Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Free Cash Flow (2016 - 2025)

Angiodynamics (ANGO) has disclosed Free Cash Flow for 16 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 230.63% year-over-year to $4.3 million, compared with a TTM value of -$8.7 million through Nov 2025, up 67.57%, and an annual FY2025 reading of -$14.6 million, up 52.43% over the prior year.
  • Free Cash Flow was $4.3 million for Q4 2025 at Angiodynamics, up from -$16.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $18.2 million in Q2 2025 and bottomed at -$26.7 million in Q3 2023.
  • Average Free Cash Flow over 5 years is -$2.8 million, with a median of $1.0 million recorded in 2023.
  • The sharpest move saw Free Cash Flow skyrocketed 900.26% in 2022, then crashed 1965.48% in 2024.
  • Year by year, Free Cash Flow stood at -$777000.0 in 2021, then surged by 900.26% to $6.2 million in 2022, then decreased by 24.61% to $4.7 million in 2023, then tumbled by 72.08% to $1.3 million in 2024, then surged by 230.63% to $4.3 million in 2025.
  • Business Quant data shows Free Cash Flow for ANGO at $4.3 million in Q4 2025, -$16.7 million in Q3 2025, and $18.2 million in Q2 2025.